Depigmenting mechanism of NSAIDs on B16F1 melanoma cells

Arch Dermatol Res. 2011 Apr;303(3):171-80. doi: 10.1007/s00403-010-1094-8. Epub 2010 Nov 16.

Abstract

The aim of the present work was to clarify the anti-melanogenic mechanism of non-steroidal anti-inflammatory drugs (NSAIDs). Mefenamic acid, diclofenac, and nimesulide were used in this study, and these drugs inhibit melanin synthesis in B16F1 melanoma cells. To elucidate the anti-melanogenic mechanism of NSAIDs, we performed western blotting analysis for melanogenic proteins, such as tyrosinase, TRP-1, and TRP-2. All NSAIDs used in this study inhibited tyrosinase protein level. Semi-quantitative RT-PCR analysis showed that the depigmentation effect of mefenamic acid and nimesulide might be due to the inhibition of tyrosinase gene transcription. These results indicate that NSAIDs inhibit α-MSH-enhanced melanin synthesis, and are candidate anti-melanogenic agents since they might be effective in hyperpigmentation disorders.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Diclofenac / pharmacology
  • Humans
  • Intramolecular Oxidoreductases / genetics
  • Intramolecular Oxidoreductases / metabolism
  • Mefenamic Acid / pharmacology
  • Melanins / metabolism*
  • Melanoma, Experimental
  • Mice
  • Monophenol Monooxygenase / genetics
  • Monophenol Monooxygenase / metabolism*
  • Oxidoreductases / genetics
  • Oxidoreductases / metabolism
  • Pigmentation Disorders / drug therapy*
  • Skin Pigmentation / drug effects*
  • Sulfonamides
  • alpha-MSH / metabolism

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Melanins
  • Sulfonamides
  • Diclofenac
  • Mefenamic Acid
  • alpha-MSH
  • Oxidoreductases
  • tyrosinase-related protein-1
  • Monophenol Monooxygenase
  • Intramolecular Oxidoreductases
  • dopachrome isomerase
  • nimesulide